SimBioSys Secures FDA Clearance for TumorSight® Risk, Introducing the World’s First AI-Powered, MRI-Derived Breast Cancer Recurrence Risk Assessment

SimBioSys® announced US FDA 510(k) clearance of TumorSight® Risk, the world’s first AI-powered, MRI-derived prognostic tool for assessing breast cancer recurrence risk.